eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

AMPLIFY CLINICAL TRIAL

In AMPLIFY, ELIQUIS (apixaban) demonstrated comparable efficacy with significantly fewer major bleeding events vs. enoxaparin / warfarin in patients receiving treatment for DVT / PE1

* Efficacy analyses based on ITT population for whom the outcome status at 6 months was documented. Safety analyses based on patients who had at least one dose of study drug.

Diagnosemethoden

ELIQUIS dosing for your patients with DVT / PE is simple: START twice daily, STAY twice daily3

It’s simple to switch your patients to ELIQUIS3

Dosing may differ for some patients with renal impairment – please also see recommendations for patients with hepatic impairment3

View information to assist your daily practice, including adverse reactions, contraindications and interactions


Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

AMPLIFY = Apixaban for the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis as First-Line Therapy   
ARR = Absolute Risk Reduction   
BD = Twice Daily   
CI = Confidence Interval   
DVT = Deep Vein Thrombosis   
INR = International Normalised Ratio   
ITT = Intention-To-Treat   
LMWH = Low Molecular Weight Heparin   
N = Total number of patients in either the ELIQUIS group or the enoxaparin / warfarin group   
n = Number of patients with event   
PE = Pulmonary Embolism   
RR = Relative Risk   
RRR = Relative Risk Reduction   
SC = Subcutaneous   
VTE = Venous Thromboembolic Events

Not all patients who start on ELIQUIS for acute DVT / PE will stay on ELIQUIS; some acute DVT / PE patients who receive treatment do not require treatment for the prevention of recurrent DVT / PE. Other patients may be prescribed ELIQUIS for the prevention of recurrent VTE after initial treatment for acute DVT / PE with another anticoagulant.3 This is a decision for the prescribing clinician together with patient involvement in the decision-making.

References

  1. Agnelli G et al. N Engl J Med 2013; 369: 799–808.
  2. Agnelli G et al. N Engl J Med 2013; 369: 799–808.Supplementary appendix.
  3. ELIQUIS® (apixaban) Summary of Product Characteristics.